MarketCap
Facebook
X
TelegramAnnual report 2025
added 11-19-2025
Enanta Pharmaceuticals Long-Term Debt 2011-2026 | ENTA
Long-term debt is a financial obligation of a company or an individual with a repayment period exceeding one year from the date it arises. In accounting, such obligations are recorded under the "long-term liabilities" section.
Main characteristics:- Term exceeds 12 months
- Can take the form of bonds, bank loans, credit lines, leasing, or loans from affiliated parties
- Repaid through regular payments (interest and/or principal) over several years
- Investment in development
Allows financing of large projects — new factories, production lines, innovative developments — without diverting working capital. - Smoothing of cash flows
A long-term payment schedule facilitates budget planning and reduces short-term financial risks. - Optimization of capital structure
A combination of equity and borrowed capital can reduce the average cost of business financing.
A high level of long-term debt may indicate that a company heavily relies on borrowed funds. This increases risks, especially in conditions of rising interest rates or declining profits. However, a moderate level of debt can signal a sound growth strategy — for example, the company takes a loan to expand its business.
If a company uses borrowed funds effectively (e.g., invests in profitable projects), this can lead to profit growth and, consequently, an increase in stock value. An investor evaluates whether the investments made using debt are paying off.
It is important to monitor whether the company can regularly pay interest and repay the principal. Payment difficulties can lead to reduced dividends, a drop in stock value, and even bankruptcy.
Examples of long-term debt:- Mortgage loans for property purchases
- Corporate bonds issued by a company to raise capital
- Project financing — long-term loans for building or expanding production facilities
- Leasing obligations for equipment or transport
Annual Long-Term Debt Enanta Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 54.8 M | 53.9 M | 21.2 M | 22.4 M | 1.13 M | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 54.8 M | 1.13 M | 30.7 M |
Quarterly Long-Term Debt Enanta Pharmaceuticals
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 55.7 M | 56.5 M | 56.5 M | 53.9 M | 48.1 M | 43.4 M | 20.5 M | 21.2 M | 22.3 M | 23.1 M | 21.9 M | 22.4 M | 22.2 M | 15.1 M | 16 M | 1.13 M | 1.64 M | 1.13 M | 3.52 M | 3.84 M | 3.84 M | 3.84 M | 5.99 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 56.5 M | 1.13 M | 22.8 M |
Long-Term Debt of other stocks in the Biotechnology industry
| Issuer | Long-Term Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
273 M | - | 2.43 % | $ 254 M |  Germany |
 |
AgeX Therapeutics
AGE
|
13.2 M | - | -10.17 % | $ 12.2 K |  USA |
 |
Aeglea BioTherapeutics
AGLE
|
4 M | - | - | $ 1.01 B | USA |
 |
Adagene
ADAG
|
417 K | $ 1.65 | 7.91 % | $ 92.9 M |  China |
 |
Alterity Therapeutics Limited
ATHE
|
59.9 K | $ 3.59 | 1.99 % | $ 8.64 B |  Australia |
 |
Arrowhead Pharmaceuticals
ARWR
|
104 M | $ 66.05 | 2.3 % | $ 8.83 B | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
2.42 B | - | - | $ 40.3 B | USA |
 |
Autolus Therapeutics plc
AUTL
|
47.9 M | $ 1.52 | -16.3 % | $ 388 M |  Britain |
 |
Biophytis SA
BPTS
|
1.83 M | - | -13.47 % | $ 169 M |  France |
 |
Akero Therapeutics
AKRO
|
529 K | - | - | $ 3.67 B | USA |
 |
Biogen
BIIB
|
6.3 B | $ 184.48 | -1.67 % | $ 26.9 B | USA |
 |
AVROBIO
AVRO
|
188 K | - | 1083.1 % | $ 745 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
278 K | - | -1.52 % | $ 24.7 M | USA |
 |
BioNTech SE
BNTX
|
231 M | $ 102.17 | 2.32 % | $ 27.2 B | Germany |
 |
Midatech Pharma plc
MTP
|
4.76 M | - | -18.52 % | $ 27.3 M | Britain |
 |
AstraZeneca PLC
AZN
|
17.5 B | $ 93.52 | -1.2 % | $ 96.9 B | Britain |
 |
BeiGene, Ltd.
BGNE
|
166 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Bellicum Pharmaceuticals
BLCM
|
25.7 M | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
22.7 M | - | -7.31 % | $ 87 M | USA |
 |
Bristol-Myers Squibb Company
BMY
|
47.6 B | $ 55.71 | -0.28 % | $ 113 B | USA |
 |
Институт стволовых клеток человека
ISKJ
|
175 M | - | - | - |  Russia |
 |
Codiak BioSciences
CDAK
|
34.9 M | - | -55.98 % | $ 2.15 M | USA |
 |
ARCA biopharma
ABIO
|
755 K | - | 1052.0 % | $ 415 M | USA |
 |
Cerevel Therapeutics Holdings
CERE
|
380 M | - | - | $ 7.29 B | USA |
 |
Acasti Pharma
ACST
|
410 K | - | 4.01 % | $ 150 M |  Canada |
 |
Zai Lab Limited
ZLAB
|
13.7 M | $ 18.37 | -0.97 % | $ 18.2 B | China |
 |
Coherus BioSciences
CHRS
|
351 K | $ 1.61 | -5.03 % | $ 152 M | USA |
 |
Catalyst Biosciences
CBIO
|
199 K | $ 10.84 | 0.46 % | $ 714 M | USA |
 |
Caladrius Biosciences
CLBS
|
137 K | - | -16.75 % | $ 25.8 M | USA |
 |
Celldex Therapeutics
CLDX
|
2.36 M | $ 25.59 | -6.54 % | $ 1.65 M | USA |
 |
Cellectis S.A.
CLLS
|
28.8 M | $ 4.22 | -4.2 % | $ 116 M | France |
 |
Clearside Biomedical
CLSD
|
649 K | - | - | $ 25.3 M | USA |
 |
Chimerix
CMRX
|
1.18 M | - | - | $ 756 M | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
19.9 M | - | -15.15 % | $ 60.3 M | Britain |
 |
Corcept Therapeutics Incorporated
CORT
|
6.11 M | $ 37.35 | -0.4 % | $ 3.86 B | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
2.79 M | $ 23.18 | 2.02 % | $ 2.75 B | USA |
 |
AIkido Pharma
AIKI
|
2.63 M | - | 1.93 % | $ 17.4 M | USA |
 |
Albireo Pharma
ALBO
|
9.62 M | - | -0.23 % | $ 916 M | USA |
 |
CureVac N.V.
CVAC
|
25.4 M | - | - | $ 867 M | Germany |
 |
Acer Therapeutics
ACER
|
146 K | - | 2.71 % | $ 14 M | USA |
 |
Alpine Immune Sciences
ALPN
|
3.38 M | - | - | $ 2.17 B | USA |
 |
AlloVir
ALVR
|
16.6 M | - | 4.14 % | $ 49.1 M | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
44.6 M | $ 55.11 | 3.49 % | $ 4.45 B | USA |
 |
CRISPR Therapeutics AG
CRSP
|
206 M | $ 55.17 | 2.47 % | $ 4.65 B |  Schweiz |
 |
Ayala Pharmaceuticals
AYLA
|
1.33 M | - | - | $ 7.46 M |  Israel |
 |
Zentalis Pharmaceuticals
ZNTL
|
43.2 M | $ 3.53 | -5.75 % | $ 231 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
274 K | - | -11.43 % | $ 502 K | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
614 M | $ 29.43 | 6.09 % | $ 1.43 B | USA |